Status:
COMPLETED
Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine
Lead Sponsor:
Albert Schweitzer Hospital
Conditions:
Malaria
Eligibility:
All Genders
2-7 years
Phase:
PHASE4
Brief Summary
Quinine remains the treatment of choice of hospitalised malaria cases. The long treatment duration of 7 days, and adverse reactions often hamper its adequate use. Reducing the treatment duration by ad...
Detailed Description
One main concern of clinicians in malaria endemic areas is to find a simple malaria treatment with short treatment duration. The concept of combination therapy, which may reduce treatment duration and...
Eligibility Criteria
Inclusion
- Uncomplicated falciparum malaria
- Asexual parasitaemia between 20,000 and 200,000/µL
- No mixed plasmodial infection
- Fever with temperature above 38 °C or history of fever during the preceding 24 hours
- No effective anti-malarial treatment for the present attack
- Informed consent
Exclusion
- Haemoglobin \< 7 g/dL
- Packed-cell volume \< 20%
- White cell count \> 16,000/µL
- Platelet count \< 40,000/µL
- Schizontaemia \> 50/µL
- Impaired consciousness
- Convulsions or history of convulsions
- Concomitant diseases masking assessment of response
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00167739
Start Date
April 1 2003
End Date
February 1 2004
Last Update
September 21 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Research Unit, Lambaréné
Lambaréné, Moyen-Ogooué Province, Gabon, B.P. 118